LEADS BIOLABS-B (09887) Surges Over 5% as VELIXENT™ Receives Orphan Drug Designation from European Commission
Stock News
Jan 23
LEADS BIOLABS-B (09887) rose more than 5%, with a gain of 4.94% at the time of writing to HK$55.2, and a turnover of HK$18.0035 million.
On January 22, LEADS BIOLABS-B announced that on January 22, 2026, the European Commission (EC) issued an executive decision dated January 9, 2026, granting orphan drug designation to the PD-L1/4-1BB bispecific antibody VELIXENT™ (Opatisumimab, LBL-024) for the treatment of extra-pulmonary neuroendocrine carcinoma.
This marks the second orphan drug designation for VELIXENT™, following its prior designation by the U.S. Food and Drug Administration (FDA), representing another significant milestone in the global development progress of VELIXENT™.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.